TREE NEWS update: Huahai Pharmaceutical announced it expects net profit attributable to shareholders of 1.028 billion to 1.103 billion yuan for the first three quarters of 2026, up roughly 170% to 190% from 380 million yuan a year earlier. Non-recurring net profit is forecast at 662 million to 743 million yuan, up about 145% to 175%. Growth stems from API, domestic formulation and US formulation businesses, plus arbitration-related gains, proceeds from a subsidiary stake disposal and lower R&D expenses.
Huahai Pharmaceutical Forecasts 170%-190% Profit Growth for First Three Quarters of 2026
AI take
The headline growth figure overstates the operating story: a meaningful share of the uplift comes from arbitration gains, a subsidiary stake disposal and lower R&D spending, none of which are recurring. That distinction matters for anyone tracking the underlying API and formulation franchises, which are cited as the durable drivers. Whether the non-recurring items flatter the comparison base, and whether R&D normalizes, is the open question.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
6m ago
Europe’s Stoxx 600 Index Extends Decline to 1%
11m ago
Iran Says It Will Soon Block ‘Illegal’ Passage Through Strait of Hormuz
17m ago
Spot silver falls below $60/oz, down 2.2% on the day
18m ago
Cui Dongshu: China holds 62% of global NEV passenger car share in Jan-Aug 2026
22m ago
Shanghai National Day Holiday Consumption Hits 76.24B Yuan, Up 9.9%
25m ago
Road King delays Hong Kong court hearing on offshore debt restructuring to Oct 26